Fallopian Tube Cancer Clinical Trials in Philadelphia, Pennsylvania

8 studies are recruiting for fallopian tube cancer in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with folate receptor alpha (FRα) -expressing advanced-stage serous …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 275612, Philadelphia, Pennsylvania

   Locations

   70 in total

   Run by

   AbbVie

   See if you can join NCT06890338 on ClinicalTrials.gov

2. A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

   This study is researching an investigational drug called REGN5668 : * alone or, * combined with cemiplimab (also known as REGN2810) or, * combined with both cemiplimab and fianlimab (also known as REGN3767), or * combined with ubamatamab (also known as REGN4018), with or without sarilumab. The main…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   28 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT04590326 on ClinicalTrials.gov

3. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

   This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

   Locations

   82 in total

   Run by

   Artios Pharma Ltd

   See if you can join NCT04657068 on ClinicalTrials.gov

4. An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

   The Principal Investigator hypothesizes the combination of MIRV and Olaparib is an effective, and tolerable, maintenance therapy strategy in platinum sensitive recurrent ovarian cancer.

   Stage

   Phase 2

   Ages

   18 to 100

   Site

   University of Pennsylvania Health System, Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania

   Locations

   6 in total

   Run by

   University of Colorado, Denver

   See if you can join NCT05887609 on ClinicalTrials.gov

5. Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

   This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   9 in total

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT05287451 on ClinicalTrials.gov

6. CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

   A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   66 in total

   Run by

   TORL Biotherapeutics, LLC

   See if you can join NCT06690775 on ClinicalTrials.gov

7. Study of AVZO-021 in Patients With Advanced Solid Tumors

   This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sidney Kimmel Cancer Center (SKCC) at Jefferson Health, Philadelphia, Pennsylvania

   Locations

   13 in total

   Run by

   Avenzo Therapeutics, Inc.

   See if you can join NCT05867251 on ClinicalTrials.gov

8. Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

   This is a phase 2 study to test the effectiveness (anti-tumor activity) of the combination of the study drugs, Senaparib and Temozolomide, in patients with clear cell or endometrioid ovarian cancers that have ARID1A pathologic variants.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania

   Locations

   2 in total

   Run by

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

   See if you can join NCT06617923 on ClinicalTrials.gov